Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Glargine vs NPH Insulin in Insulin Resistant T2DM
NCT01854723Phase 4Withdrawn
- Start
- Apr 2013
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin isophane in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoint: Difference in A1C between groups at 6 months. Planned start Apr 2013; status: withdrawn.
02
Drugs
insulin isophane
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01854723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01854723.